



5-11-04

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 147060075 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 10, 2004

Signature:

(Annette Devereux)

Docket No.: AO-MAXC:002US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Linda N. Liu et al.

Application No.: 10/781,440

Confirmation No.:

Filed: February 18, 2004

Art Unit: N/A

For: **LOADING OF CELLS WITH ANTIGENS BY
ELECTROPORATION**

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 10/781,440

Docket No.: AO-MAXC:002US

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. AO-MAXC:002US. A duplicate copy of this paper is enclosed.

Dated: May 10, 2004

Respectfully submitted,

By 

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/781,440
		Filing Date	February 18, 2004
		First Named Inventor	Linda N. Liu
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	1	Attorney Docket Number	AO-MAXC:002US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 25 References
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	FULBRIGHT & JAWORSKI L.L.P. Melissa W. Acosta
Signature	
Date	May 10, 2004

Transmittal	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 147060075 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: May 10, 2004	Signature: Annette Devereux



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/781,440
				Filing Date	February 18, 2004
				First Named Inventor	Linda N. Liu
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	AO-MAXC:002US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-20030073238	04-17-2003	Dzekunov et al.	
	AB	US-20040009194	01-15-2004	Andrieu et al.	
	AC	US-5962318	10-05-1999	Rooney et al.	
	AD	US-20040022813	02-05-2004	Bystryn	
	AE	US-6306388	10-23-2001	Nair et al.	
	AF	US-20020058317	05-16-2002	Zimmermann	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-03012086	02-13-2003	Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A.		
	BB	WO-03012085	02-13-2003	Sigma Tau Industrie Farmaceutiche Riunite, S.P.A.		
	BC	WO-0239951	05-23-2002	Globe Immune, Inc.		
	BD	WO-03100040	12-04-2003	Merck Patent GMBH		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
A	CA	Foged et al, "Targeting Vaccines to Dendritic Cells," Pharmaceutical Research Vol. 19, No. 3, March 2002, pp 229 - 238.			
B	CB	Colino et al, "Dendritic Cells, new tools for vaccination," Microbes and Infection 5, 2003, pp. 311-319.			
C	CC	Wildera et al, "Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo," The Journal of Immunology Vol. 165, 2000, pp. 4635-4640.			
D	CD	Mir et al, "Therapeutic Perspectives of In Vivo Cell Electroporation," Bioelectrochemistry 53, 2000, pp 1- 10.			
E	CE	Taylor et al, "Human Tumour and Dendritic Cell Hybrids Generated by Electroporation: Potential for Cancer Vaccines," Biochimica et Biophysics Acta 1500, 2000, pp 265 - 279.			
F	CF	Li et al, "Delivery of Exogenous Antigen into the Major Histocompatibility Complex Class I and Class II Pathways by Electroporation," Journal of Leukocyte Biology Vol. 56, November 1994, pp. 616 - 624.			
G	CG	Chen et al, "Electroporation and Commercial Liposomes efficiently Deliver Soluble Protein into the MHC Class I Presentation Pathway," Journal of Immunological Methos Vol. 160, 1993, pp 49-57.			
H	CH	Harding, Clifford, "Electroporation of Exogenous Antigen into the Cystol for Antigen Processing and Class I Major Histocompatibility Complex (MHC) Presentation: Weak Base Amines and Hypothermia (18 C) Inhibit the Class I MHC Processing Pathway," Eur. J. Immunology Vol. 22,			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/781,440
				Filing Date	February 18, 2004
				First Named Inventor	Linda N. Liu
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	AO-MAXC:002US

		1992, pp 1865 - 1869.	
	CI	Kuroki et al, "Significance of Tumor-associated Antigens in the Diagnosis and Therapy of Cancer, an Overview," Anticancer Research Vol. 22, 2002, pp. 4255 - 4264.	
	CJ	Asavaroengchai et al, "Tumor Lysate-pulsed Dendritic Cells can Elicit an Effective Antitumor Immune Response During Early Lymphoid Recovery," PNAS Vol. 99, No.2 , January 22, 2002, pp. 931-936.	
	CK	Holti et al, "Immunotherapy of Metastatic Renal Cell Carcinoma with Tumor Lysate-pulsed Autologous Dendritic Cells," Clinical Cancer Research Vol. 8, November 2002, pp. 3369 - 3376.	
	CL	Herr et al, "Mature Dendritic Cells Pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte Responses," Blood Vol. 96, No. 5, September 1, 2000, pp 1857 - 1864.	
	CM	Geiger et al, "Vaccination of Pediatric Solid Tumor Patients with Tumor Lysate-pulsed Dendritic Cells Can Expand Specific T Cells and Mediate Tumor Regression," Cancer Research Vol. 61, December 1, 2001, pp. 8513 - 8519.	
	CN	Shnerr et al, "Apoptotic Pancreatic Tumor Cells are Superior to Cell Lysates in Promoting Cross-Priming of Cytotoxic T Cells and Activate NK and YB T Cells," Cancer Research Vol. 62, april 15, 2002, pp. 2347 - 2352.	
	CO	Kim et al, "Enhancement of Antitumor Immunity by Dendritic Cells loaded with Exogenous Antigen by Electroporation," Experimental Biology 2002: Meeting Abstracts, pg A664.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. ER 147060075 US in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on May 10, 2004
Date



Signature

Annette Devereux

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant